Clinical trials: Human Papilloma Virus Vaccine
Infections, Papillomavirus, Papillomavirus Vaccines
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00359619
- Testing
- CervarixTM, HPV investigational vaccine GSK568893A, different formulations
- Where
- 10 sites in United States, Belgium
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
This long-term extension study evaluates the persistence of neutralizing antibody responses to a bivalent human papillomavirus vaccine in females who previously participated in study 311-HPV-1004 (NCT02740777).
- Trial name
- NCT07820241
- Testing
- Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)
- Where
- 2 sites in China
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HPV Vaccine Acceptability
A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men
The purposes of this study are to (1) identify predictors of Human papillomavirus (HPV) vaccine acceptability among college men based on the Health Belief Model through focus groups, (2) triangulate focus group results with a…
- Trial name
- NCT01431079
- Testing
- HPV vaccine acceptability
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
HPV-Related Squamous Cell Carcinoma
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts…
- Trial name
- NCT04180215
- Testing
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab.
- Where
- 34 sites in United States, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Hookipa Biotech GmbH
Vaccine Reaction
Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System
The goal of this clinical trial is to evaluate the safety and immunogenicity of an HPV Vaccine (Gardasil) delivered by intramuscular needle-free injection and intradermal needle-free injection.
- Trial name
- NCT06142461
- Testing
- Gardasil, PharmaJet Stratis® Needle-Free Injection System, PharmaJet Tropis® Needle-Free Injection System
- Where
- Indonesia
- Volunteers
- healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Human Papillomavirus Vaccines
Increasing Optimal Use of HPV Vaccination in Primary Care
Washington University will evaluate the effectiveness of a multi-component implementation strategy to increase use of HPV vaccine in primary care practices.
- Trial name
- NCT04180462
- Testing
- Practice Facilitation, Education, Audit and Feedback
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Randomized, 2-arm observational study. The 2 arms (randomized at the level of health care provider) will be: 1. usual practice; 2.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02558803
- Testing
- Simple Reminder
- Where
- 5 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Regenstrief Institute, Inc.
Human Papilloma Virus
Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise
The goal of this study is to engage rural primary care clinics and community organizations to test interventions designed to increase HPV vaccinations in both male and female patients aged 9-26 years.
- Trial name
- RAVE (NCT03604393)
- Testing
- Practice facilitation
- Where
- United States
- Volunteers
- 22,000 people
- Sponsor
- Oregon Health and Science University
Human Papillomavirus Vaccine
HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial
A randomized, observer-blind non-inferiority trial to evaluate alternative human papillomavirus (HPV) vaccination schedules in young females in West Africa.
- Trial name
- HPV (NCT03832049)
- Testing
- 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
- Where
- The Gambia
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Cervical Cancer
Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities
Primary care physicians have an important role to play in the delivery of cancer prevention and detection services to patients. Face-to-face counseling of physicians, called academic detailing, involves a brief and focused…
- Trial name
- NCT00629993
- Testing
- Academic Detailing
- Where
- United States
- Volunteers
- 282 people, healthy volunteers welcome
- Sponsor
- Columbia University
Human Papilloma Virus Vaccine
The STOP-HPV Scale Up Study
Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices…
- Trial name
- NCT06831383
- Testing
- STOP-HPV-Online, STOP-HPV-LC
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- University of California, Los Angeles
HPV Vaccine Attitudes, HPV Vaccine Intention
HPV Vaccine Acceptability Among Young Men Who Have Sex With Men
The FDA has recently approved Gardasil for the prevention of anal cancer in people aged 9-26. Men who have sex with men (MSM) have disproportionately high rates of anal cancer and could benefit greatly from vaccination.
- Trial name
- NCT01535794
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Indiana University
Cervical Intraepithelial Neoplasia
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
This study was designed to enable all subjects who received placebo in the HPV-039 study (NCT00779766), to also receive GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed.
- Trial name
- NCT03629886
- Testing
- HPV (Types 16, 18) Vaccine, Adsorbed
- Where
- 4 sites in China
- Volunteers
- 6,051 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections, Papillomavirus Vaccines
Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers
Randomized clinical trial with two groups, with a test-retest model, with single-blind approach, using a probabilistic sampling and the population was mothers of girls aged 9 to 12 years from a public elementary school in the…
- Trial name
- NCT06854354
- Testing
- HPV Prevention Vaccine
- Where
- Mexico
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hospital Univeristario Benemerita Universidad Autonoma de Puebla
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or…
- Conditions
- Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
- Trial name
- AHEAD-MERIT (NCT04534205)
- Testing
- BNT113, Pembrolizumab
- Where
- 138 sites in United States, Argentina and 19 more
- Volunteers
- 358 people
- Sponsor
- BioNTech SE
Papillomavirus Infections
The KEN SHE Study on HPV-vaccine Efficacy
The KEN SHE Study aims to identify effective cervical cancer prevention strategies. Cervical cancer is caused by an infection with Human Papillomavirus, also called HPV.
- Trial name
- NCT03675256
- Testing
- immediate Gardasil 9, delayed MenVeo vaccine, immediate MenVeo vaccine, delayed Gardasil 9, immediate Cervarix, delayed MenVeo vaccine
- Where
- 3 sites in Kenya
- Volunteers
- 2,275 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
HPV, HPV Vaccine
Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers
This study evaluates whether different types of digital health communication can increase parents' intention to vaccinate their daughters against human papillomavirus (HPV) in Nigeria.
- Trial name
- NCT07498075
- Testing
- Chatbot counseling, Misinformation-resistance pre-bunking inoculation, Short edutainment
- Where
- Nigeria
- Volunteers
- 3,340 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Healthy Subject
mHealth Intervention in Increasing HPV Vaccinations in College Students
This randomized pilot trial studies how well a mobile health (mHealth) intervention works in increasing human papillomavirus (HPV) vaccination among college students at the Ohio State University.
- Trial name
- NCT02960100
- Testing
- Informational Intervention, Media Intervention, Survey Administration
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Infections, Papillomavirus
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is…
- Trial name
- NCT00652938
- Testing
- HPV Vaccine (GSK580299) Cervarix TM, Engerix B
- Where
- 7 sites in Netherlands, Sweden
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus
9-valent HPV Vaccine in Postpartum Women
This study will evaluate the immunogenicity of the 9-valent HPV vaccine in post-partum women age 16-45.
- Trial name
- NCT04311528
- Testing
- 9-valent HPV vaccine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Augusta University